PMV Pharmaceuticals (PMVP) Income from Continuing Operations (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Income from Continuing Operations came in at 18038000.0 in Q1 2026, down 3.45% YoY from 18683056.2 in Q1 2025, and little changed on a QoQ basis from 18060000.0 in Q4 2025.
PMV Pharmaceuticals (PMVP) Income from Continuing Operations (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Income from Continuing Operations data on file, last reported at 18038000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 3.45% year-over-year to 18038000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 78367000.0 (down 28.53% YoY) and the FY2025 annual result came in at 77765000.0, down 32.24% from the prior year.
- Income from Continuing Operations was little changed at 18038000.0 in Q1 2026, from 18060000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1213000.0 in Q2 2024 to a low of 23096000.0 in Q4 2024.
- A 5-year average of 17463764.71 and a median of 18060000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 93.04% — and 2025, when it tumbled 1648.56%.
- Tracing PMVP's Income from Continuing Operations over 5 years: stood at 19345000.0 in 2022, then gained by 18.55% to 15756000.0 in 2023, then sank by 46.59% to 23096000.0 in 2024, then increased by 21.8% to 18060000.0 in 2025, then gained by 0.12% to 18038000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 18038000.0 (Q1 2026), 18060000.0 (Q4 2025), and 21059000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | -18.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.04 Mn |
| Dec 31, 2025 | -18.06 Mn |
| Sep 30, 2025 | -21.06 Mn |
| Jun 30, 2025 | -21.21 Mn |
| Mar 31, 2025 | -17.44 Mn |
| Dec 31, 2024 | -23.10 Mn |
| Sep 30, 2024 | -19.23 Mn |
| Jun 30, 2024 | -1.21 Mn |
| Mar 31, 2024 | -15.27 Mn |
| Dec 31, 2023 | -15.76 Mn |
| Sep 30, 2023 | -16.64 Mn |
| Jun 30, 2023 | -17.44 Mn |
| Mar 31, 2023 | -19.13 Mn |
| Dec 31, 2022 | -19.35 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -17.31 Mn |
| Mar 31, 2022 | -18.43 Mn |
| Dec 31, 2021 | -18.36 Mn |
| Sep 30, 2021 | -15.01 Mn |
| Jun 30, 2021 | -12.87 Mn |